trial

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

NCTId NCT07288333
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 120 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2027-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-02-16
Primary completion
2027-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
NBI-1117570

Sponsors

Neurocrine BiosciencesLead Sponsor

Investigators

1
Clinical Development LeadStudy Director

Sites

5 total
Kazanlak, BulgariaPazardzhik, BulgariaTargovishte, BulgariaLondon, United KingdomOxford, United Kingdom

Linked catalysts

1
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia — primary completion2027-08

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE2
Primary Completion Date
2027-08
Status
RECRUITING
relationships
The graph out of here
drug
NBI-1117570
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Development Lead
person